TScan Therapeutics, Inc. (TCRX) Reports In-Line Q2 EPS

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q2 EPS of ($0.28), in-line with the analyst estimate of ($0.28). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Trump Bought At Least $100,001 In Palantir Shares, Disclosure Shows - Bloomberg
• Largo wins $125M U.S. defense contract for vanadium pentoxide supply
• Goldman Sachs Upgrades Lumo Kodit Oyj (LUMO:FH) to Buy